Navigation Links
Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
Date:9/28/2010

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the market-leading drug, Novartis's Diovan/Tareg, will suffer the greatest decline as its sales will decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition — these drug classes are the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.

"Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic antihypertensive drugs," said Decision Resources Analyst Taskin Ahmed. "Through 2019, we do not forecast blockbuster sales for any of the emerging antihypertensive agents."

The Pharmacor 2010 findings also reveal that, although the overall market will decline, sales of therapies offering greater convenience, such as fixed-dose combinations, will increase over the next several years. The CCB/ renin-angiotensin-aldosterone system (RAAS) inhibitor fixed-dose combinations and CCB/RAAS inhibitor/diuretic fixed-dose combinations will capitalize on this opportunity, generating approximately $6 billion in total sales in 2019.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
7. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 18, 2017 BD (Becton, Dickinson and Company) (NYSE: ... it will host a live webcast of its Annual Meeting of ... The webcast can be accessed from the BD corporate ... Tuesday, January 31, 2017. ... About BD BD is a global medical technology ...
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Executives 2017 in its continued commitment to the advancement of the clinical trials ... current issues related to clinical trial planning and management. , As executive ...
(Date:1/18/2017)... Frederick, Maryland (PRWEB) , ... January 18, 2017 ... ... of two new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of ... Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the ...
Breaking Biology Technology:
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):